{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022908","form_type":"8-K","ticker":null,"cik":"0001362703","company_name":"THERALINK TECHNOLOGIES, INC.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.567529+00:00","generated_at":"2026-06-13T14:45:25.113354+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theralink appoints Faith Zaslavsky as CEO; Mick Ruxin becomes CMO","bullets":["Faith Zaslavsky appointed CEO effective June 26, 2023; previously President and COO since December 2022.","Former CEO Mick Ruxin transitions to Chief Medical Officer.","Company is in process of merging with IMAC Holdings, Inc. (NASDAQ: BACK).","Zaslavsky has over 23 years of genomics experience, including commercializing BRCA tests."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022908","json":"https://secwatch.observer/filing/0001493152-23-022908.json","markdown":"https://secwatch.observer/filing/0001493152-23-022908.md","text":"https://secwatch.observer/filing/0001493152-23-022908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/0001493152-23-022908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:45:25.113354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"324926b830","claim":"Faith Zaslavsky was appointed as Chief Executive Officer at THERALINK TECHNOLOGIES, INC..","evidence_excerpt":"Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/0001493152-23-022908-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9c01024b8c","claim":"Mick Ruxin changed role as Chief Medical Officer at THERALINK TECHNOLOGIES, INC..","evidence_excerpt":"The Company’s former Chief Executive Officer, Mick Ruxin, M.D. has transitioned to become the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1362703/000149315223022908/0001493152-23-022908-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}